Eric Wininger, MD
Endocrinology, Diabetes & Metabolism · Freehold, NJNPI 1750489340
Payments from drug & device makers
Across 572 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Sanofi-aventis U.S. LLC$1K
- Boehringer Ingelheim$686
- Lilly USA, LLC$667
- AstraZeneca$549
- Abbott$489
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$6878%
- Food & beverage$7,46691%
- Education$511%
- Gifts$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 154 | $1,902 |
| Sanofi-aventis U.S. LLC | 84 | $1,246 |
| Boehringer Ingelheim | 51 | $686 |
| Lilly USA, LLC | 51 | $667 |
| AstraZeneca(2 entities) | 36 | $549 |
| Abbott | 33 | $489 |
| AbbVie | 29 | $388 |
| Sanofi US Services Inc. | 1 | $350 |
| Johnson & Johnson | 27 | $343 |
| Merck | 20 | $255 |
| Amarin Pharma, Inc. | 17 | $217 |
| Insulet Corporation | 14 | $194 |
| Sanofi | 2 | $177 |
| Bayer | 8 | $119 |
| Amneal Pharmaceuticals LLC | 9 | $110 |
| Lifescan, Inc. | 5 | $77 |
| Medtronic(2 entities) | 4 | $72 |
| Xeris Pharmaceuticals, Inc. | 5 | $63 |
| Mannkind Corporation | 5 | $61 |
| Dexcom, Inc. | 3 | $46 |
| BETA Bionics, Inc. | 1 | $26 |
| Sekisui Diagnostics LLC | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $16 |
| Companion Medical, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| BD | 1 | $14 |
| Amgen | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Cequr Corporation | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
| IBSA Pharma Inc. | 1 | $12 |
| Senseonics, Incorporated | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$455
How this compares
$8,230 in reported general payments places this provider in the 75th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 414 | $825,744 |
| TrulicityDulaglutide | 180 | $311,692 |
| JardianceEmpagliflozin | 228 | $295,166 |
| FarxigaDapagliflozin Propanediol | 156 | $217,656 |
| Tresiba Flextouch U-100Insulin Degludec | 221 | $177,723 |
| MounjaroTirzepatide | 67 | $134,788 |
| JanuviaSitagliptin Phosphate | 90 | $109,899 |
| InvokanaCanagliflozin | 62 | $85,286 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $65,929 |
| RybelsusSemaglutide | 25 | $60,758 |
| Humalog Kwikpen U-100Insulin Lispro | 119 | $60,062 |
| TradjentaLinagliptin | 56 | $56,521 |
| Xigduo XrDapaglifloz Propaned/Metformin | 42 | $48,212 |
| Novolog FlexpenInsulin Aspart | 120 | $43,149 |
| JanumetSitagliptin Phos/Metformin Hcl | 28 | $33,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,902 | $886,502439 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Baqsimi, Humalog | $667 | $464,479294 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $686 | $374,553299 claims |
| AstraZenecaFarxiga | $549 | $217,656156 claims |
| MerckJanuvia, Janumet, Janumet Xr | $255 | $160,942136 claims |
| Johnson & JohnsonInvokana | $343 | $85,28662 claims |
| AbbVieSynthroid | $388 | $25,529293 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $1,246 | $23,22834 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $110 | $10,782883 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Freehold
- Kenneth OrdeneFreehold$109K
- Melissa YoungFreehold$20K
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Taher ModarressiPennington$414K
- Navtika DesaiHillsborough$408K
- Atara SchultzTeaneck$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.